However, molecular mechanisms underlying its observed beneficial effects in ALD models may still include residual PPARγ action since partial conversion of (R)‐ (PPARγ inactive) to (S)‐(PPARγ active) pioglitazone occurs between dosing intervals in cell culture and in vivo.11 This evidence concerns the gene PPARG and adrenoleukodystrophy.